Eyes on the prize: Bringing individualized therapy from the bedside to clinical practice

Pharmacogenomics

Volumn 8, Issue 10, 2007, Pages 1295-1298

  Peters, Eric J ^a  

^a University of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BRCA1 PROTEIN; BRCA2 PROTEIN; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOXETINE; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; MERCAPTOPURINE; PAROXETINE; TAMOXIFEN; THIOPURINE METHYLTRANSFERASE; TRASTUZUMAB; WARFARIN;

BLEEDING; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DOSE CALCULATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUSTRY; DRUG LABELING; DRUG RESEARCH; DRUG SAFETY; ENZYME ACTIVITY; ENZYME DEFICIENCY; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; HEALTH CARE ORGANIZATION; HOMOZYGOSITY; HOT FLUSH; HUMAN; INDIVIDUALIZATION; INFORMATION PROCESSING; INFORMED CONSENT; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; MEDICOLEGAL ASPECT; METHODOLOGY; NEUTROPENIA; PANCYTOPENIA; PATIENT ADVOCACY; PATIENT CARE; PATIENT INFORMATION; PHARMACOGENOMICS; PRACTICE GUIDELINE; PRESCRIPTION; RACE DIFFERENCE; RACISM; RISK REDUCTION; SAMPLE SIZE; SOCIAL ASPECT; TREATMENT OUTCOME; UNITED STATES;

CLINICAL TRIALS AS TOPIC; HUMANS; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 36448985637     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.10.1295     Document Type: Conference Paper

References (6)

1. Cuatrecasas P: Drug discovery in jeopardy. J. Clin. Invest. 116, 2837-2842 (2006).
2. DiMasi JA, Hansen RW, Grabowski HG: The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-185 (2003).
3. Terry SF, Terry PF, Rauen KA, Uitto J, Bercovitch LG: Advocacy groups as research organizations: the PXE International example. Nat. Rev. Genet. 8, 157-164 (2007).
4. Jin Y, Desta Z, Stearns V et al.: CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl Cancer Inst. 97(1), 30-39 (2005).
5. Stearns V et al.: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl Cancer Inst. 95, 1758-1764 (2003).
6. Goetz MP, Knox SK, Suman VJ et al.: The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. 101(1), 113-121 (2007).